Popular Articles

Home-visit Interventions Result In Decreased Behavioral Problems In Infants Born To Young American Indian Mothers
American Indian teenagers become parents at twice the rate of other American teenagers. Many of these teens have greater environmental and behavioral challenges associated with living on reservations, including higher rates of poverty, increased rates of unemployment and school drop-out, higher rates of alcohol and drug abuse, impaired access to healthcare, as well as increased risk of domestic violence and suicide over the general population.
new payday loan lenders
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the Company"s lead radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. The compound has shown the potential to selectively deliver lethal radiation to cancer cells. The proposed Phase 3 trial will confirm that administration of Onalta results in stabilization, regression or complete remission of the carcinoid tumor, and improves carcinoid-related symptoms when compared to a high-dose regimen of the current standard therapy for this disease, Sandostatin®. With EMEA"s approval of its proposed Phase 3 protocol in hand, Molecular Insight can proceed with the final clinical trial that will position Onalta for marketing authorization in the EU.
News of the day
Swine Flu Pandemic Twist: Humans May Infect Pigs
The strain of influenza, A/H1N1, that is currently pandemic in humans has been shown to be infectious to pigs and to spread rapidly in a trial pig population.
Mental Health

Statins Can Protect Against Alzheimer's Disease, According To New Study

High cholesterol levels are considered to be a risk factor not only for cardiovascular disease including stroke, but also for the development of Alzheimer"s disease. Therefore, many cholesterol lowering drugs, including statins, have been developed in recent years. In addition to the cholesterol reducing effect of statins Amalia Dolga, PhD, of the University of Groningen, The Netherlands, and her co-investigators have demonstrated that statins can protect nerve cells against damage which we know to occur in the brain of Alzheimer"s disease patients. The results are published in the June issue of the Journal of Alzheimer"s Disease. How nerve cells die in Alzheimer"s disease is complex but we know that nerve cells eventually die because they are strongly overstimulated, a process called excitotoxicity. In animal experiments conducted in the laboratory of Professor Ulrich Eisel, Department of Molecular Neurobiology, University of Groningen, Dolga and colleagues overstimulated such nerve cells. They clearly demonstrated that treatment with a statin called Lovastatin could prevent the death of nerve cells under these conditions. The statins not only prevented cells from dying but also prevented the loss of memory capacity that normally occurs after such cell death. In a previous study Dolga had showed that these statins stimulate the protective capacity of tumor necrosis factor, which is a key player in the brain"s immune response. Dolga has demonstrated in animal experiments that this tumor necrosis factor has a strong beneficial effect on nerve cells and can protect nerve cells against death. A widely prescribed drug like statins can activate this protective pathway revealing strong beneficial effect. IOS Press BV


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):